Projects per year
Personal profile
Biography
Professor Howard Gurney is the Director of Clinical Trials and Head of the Cancer Program for the Faculty of Medicine and Health Sciences at Macquarie University and Senior Staff Specialist in Medical Oncology at Westmead Hospital.
Dr Gurney has a firm background in clinical research and has subspecialty interests in urogenital cancers including prostate, bladder, testis and kidney cancer.
He has been the principal investigator for over 150 clinical trials and has over 150 per-reviewed publications in genitourinary cancers and pharmacogenomics, including recent papers in the New Engl J Med, Lancet and Lancet Oncology. Current research interests also include the pharmacogenomics and therapeutic monitoring of chemotherapy and targeted therapies and he has published widely in this area. He is regarded as an authority on mechanisms for safe dosing of anticancer agents and has held research grants and has written a number of invited editorials on these topics.
Fingerprint
Dive into the research topics where Howard Gurney is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
Collaborations and top research areas from the last five years
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
-
CTU: A Phase 1, open-label, dose escalation and dose expansion study, to investigate the safety, tolerability, and pharmacokinetic profile of AB521 monotherapy in participants with clear cell renal cell carcinoma and other solid tumors.
Gurney, H., Martin, L., TAIDI, G., Garcia, M., Quinlan, G. & Chapman, N.
14/07/24 → 29/05/29
Project: Research
-
V940-004: CTU: A Phase 2, Randomized, Double-blind, Clinical Study of V940 (mRNA-4157) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in the Adjuvant Treatment of Participants with Renal Cell Carcinoma
Gurney, H., Chapman, N. & Chester, C.
8/03/24 → 27/09/28
Project: Research
-
The ACRF Centre for Advanced Cancer Modelling and Experimental Oncology (COMET)
Rizos, H., Gurney, H., Shklovskaya, E., Long, G. V., Lee, J., Wang, Y., Di Ieva, A., Guller, A., Clarke AM, J. & Gupta, R.
1/01/24 → 31/12/30
Project: Research
-
CTU: A Randomized Open-Label Phase 3 Study of XL092 +Nivolumab vs Sunitinib in Subjects with Advanced or Metastatic Non-Clear Cell Renal Cell Carcinoma
Gurney, H., Chapman, N., Contacos, C., Chester, C., TAIDI, G. & Martin, L.
4/12/23 → 3/12/28
Project: Research
-
B9991046: CTU: AVELUMAB MASTER PROTOCOL: AN OPEN-LABEL CONTINUATION STUDY FOR PARTICIPANTS CONTINUING FROM PFIZER SPONSORED AVELUMAB CLINICAL STUDIES SUB-STUDY: AN OPEN-LABEL STUDY FOR CONTINUED TREATMENT ACCESS FOR PARTICIPANTS FROM THE B9991003 AVELUMAB STUDY
Gurney, H., Contacos, C., Keshiya, S., Morrisroe, E., Chapman, N. & TAIDI, G.
13/10/23 → 12/10/28
Project: Research
-
A phase II trial of nivolumab followed by ipilimumab and nivolumab in advanced non-clear-cell renal cell carcinoma
Conduit, C., Davis, I. D., Goh, J. C., Kichenadasse, G., Gurney, H., Harris, C. A., Pook, D., Krieger, L., Parnis, F., Underhill, C., Adams, D., Roncolato, F., Joshua, A., Ferguson, T., Prithviraj, P., Morris, M., Harrison, M., Begbie, S., Hovey, E., George, M., & 6 others, Feb 2024, In: BJU international. 133, Supplement 3, p. 57-67 11 p.Research output: Contribution to journal › Article › peer-review
-
Bempegaldesleukin plus nivolumab versus sunitinib or cabozantinib in previously untreated advanced clear cell renal cell carcinoma: a phase III randomized study (PIVOT-09)
Tannir, N. M., Formiga, M. N., Penkov, K., Kislov, N., Vasiliev, A., Gunnar Skare, N., Hong, W., Dai, S., Tang, L., Qureshi, A., Zalevsky, J., Tagliaferri, M. A., George, D., Agarwal, N., Pal, S. K. & List of investigators, 10 Aug 2024, In: Journal of Clinical Oncology. 42, 23, p. 2800-2811 19 p.Research output: Contribution to journal › Article › peer-review
2 Citations (Scopus) -
Clinical validation of circulating GDF15/MIC-1 as a marker of response to docetaxel and survival in men with metastatic castration-resistant prostate cancer
Mahon, K. L., Sutherland, S. I. M., Lin, H. M., Stockler, M. R., Gurney, H., Mallesara, G., Briscoe, K., Marx, G., Higano, C. S., de Bono, J. S., Chi, K. N., Clark, G., Breit, S. N., Brown, D. A. & Horvath, L. G., Jun 2024, In: Prostate. 84, 8, p. 747-755 9 p.Research output: Contribution to journal › Article › peer-review
Open AccessFile2 Citations (Scopus)43 Downloads (Pure) -
Epacadostat plus pembrolizumab versus placebo plus pembrolizumab for advanced urothelial carcinoma: results from the randomized phase III ECHO-303/KEYNOTE-698 study
Cicin, I., Plimack, E. R., Gurney, H., Leibowitz, R., Alekseev, B. Y., Parnis, F. X., Peer, A., Necchi, A., Bellmunt, J., Nishiyama, H., Clark, J., Munteanu, M., Kataria, R., Jia, C., Powles, T. & Sternberg, C. N., 25 Jul 2024, In: BMC Cancer. 23, Supplement 1, p. 1-11 11 p., 1256.Research output: Contribution to journal › Article › peer-review
Open AccessFile16 Downloads (Pure) -
First-line systemic therapy following adjuvant immunotherapy in renal cell carcinoma: an international multicenter study
El Zarif, T., Semaan, K., Xie, W., Eid, M., Zarba, M., Issa, W., Zhang, T., Nguyen, C. B., Alva, A., Fahey, C. C., Beckermann, K. E., Karam, J. A., Campbell, M. T., Procopio, G., Stellato, M., Buti, S., Zemankova, A., Melichar, B., Massari, F., Mollica, V., & 18 others, 15 Aug 2024, (Accepted/In press) In: European Urology.Research output: Contribution to journal › Article › peer-review